

location remains the same. The meeting is closed to the public.

Dated: April 22, 2004.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 04-9674 Filed 4-28-04; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Immunotoxins.

Date: May 4, 2004.

Time: 10 a.m. to 11:30 a.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone conference call.)

Contact Person: Marcia Litwack, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6206, MSC 7804, Bethesda, MD 20892. (301) 435-1719; litwackm@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel, NHLBI Competitive Supplements for Human Embryonic Stem Cell Research.

Date: May 25, 2004.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814

Contact Person: Neelakanta Ravindranath, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5140,

MSC 7843, Bethesda, MD 20892, 301-435-1034; #ravindm@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: April 22, 2004.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 04-9676 Filed 4-28-04; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Toxicology Program (NTP); National Institute of Environmental Health Sciences; The NTP Center for the Evaluation of Risks to Human Reproduction (CERHR) Expert Panel Report on the Developmental and Reproductive Toxicity of Fluoxetine: Notice of Availability and Request for Public Comments

SUMMARY: Notice is hereby given of the availability on April 19, 2004, of the Expert Panel Report on the Developmental and Reproductive Toxicity of Fluoxetine. This report includes the summaries and conclusions of the expert panel's evaluation of the scientific data for potential reproductive and/or developmental hazards associated with exposure to fluoxetine. The CERHR held this expert panel meeting March 3-5, 2004. CERHR is seeking public comment on this report and additional information about recent, relevant toxicology or human exposure studies.

Availability of Reports

This expert panel report will be available by April 19, 2004 on the CERHR Web site (<http://cerhr.niehs.nih.gov>) and in printed copy or compact disc by contacting the CERHR [P.O. Box 12233, MD EC-32, Research Triangle Park, NC 27709; telephone: (919) 541-3455; fax: (919) 316-4511; or e-mail: shelby@niehs.nih.gov].

Request for Public Comments

The CERHR invites public comments on this expert panel report and input regarding any recent, relevant toxicology or human exposure studies. The CERHR requests that all comments and other information be submitted to the CERHR at the address above by June 17, 2004.

All public comments received by the date above will be reviewed and included in the final NTP-CERHR monograph on fluoxetine to be prepared by NTP staff. The NTP-CERHR monograph will include the NTP brief, expert panel report, and all public comments received on the report. The brief will provide the NTP's interpretation of the potential for adverse reproductive and/or developmental effects to humans from exposure to fluoxetine. The NTP-CERHR monograph will be sent to appropriate federal agencies and will be available to the public and the scientific community on the CERHR web site, in hardcopy, or on compact disk.

Background

Fluoxetine hydrochloride (Prozac®; Sarafem™), an antidepressant, is a widely prescribed drug in the United States. The CERHR selected fluoxetine for evaluation because of (1) sufficient reproductive and developmental studies, (2) sufficient human exposure information, (3) changing prescription patterns, and (4) public concern about potential reproductive and/or developmental hazards associated with exposure. Fluoxetine hydrochloride, under the name Sarafem™, is prescribed to treat premenstrual dysphoric disorder (PMDD), potentially increasing the number of exposures for women of childbearing age. Furthermore, the Food and Drug Administration recently approved Prozac® for use in 7-17 year-olds thereby increasing exposures of children.

A 12-member expert panel composed of scientists from the federal government, universities, and private companies conducted an evaluation of the reproductive and developmental toxicities of fluoxetine hydrochloride (**Federal Register** Vol. 68, No. 216, pages 63122-63123, November 2003). Public deliberations by the panel took place March 3-5, 2004, at the Holiday Inn Old Town Select in Alexandria, Virginia. Following the March meeting, the draft expert panel report was revised to incorporate the panel's conclusions and subsequently reviewed by Fluoxetine Expert Panel, NTP scientists, and CERHR personnel.

Additional Information About CERHR

The NTP and the NIEHS established the NTP CERHR in June 1998 (**Federal Register** Vol. 63, No. 239, page 68782, December 1998). The purpose of the CERHR is to provide scientifically based, uniform assessments of the potential for adverse effects on reproduction and development caused

by agents to which humans may be exposed. Further information on the CERHR's chemical review process, including how to nominate chemicals for evaluation and scientists for the expert registry, can be obtained from its Web site (<http://cerhr.niehs.nih.gov>) or by contacting the CERHR directly (see address above). The CERHR also serves as a resource for information on various environmental exposures and their potential to affect pregnancy and child development. The web site has information about common concerns related to fertility, pregnancy and the health of unborn children and links to other resources for information about public health.

Dated: April 21, 2004.

Samuel H. Wilson,

Deputy Director, National Institute of Environmental Health Sciences.

[FR Doc. 04-9736 Filed 4-28-04; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Notice of Request for Applications for Strategic Prevention Framework State Incentive Grants (SPF SIG) (SP 04-002)

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice of Request for Applications for Strategic Prevention Framework State Incentive Grants (SPF SIG) (SP 04-002).

Authority: Section 516 of the Public Health Service Act.

SUMMARY: The Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Substance Abuse Prevention (CSAP) announces the availability of grant funds for Strategic Prevention Framework State Incentive Grants (SPF SIGs). SPF SIG program is one of SAMHSA's Infrastructure Grant programs. SAMHSA's Infrastructure Grant programs support an array of activities to help grantees build a solid foundation for delivering and sustaining effective substance abuse and/or mental health services. The SPF SIGs, in particular, will provide funding to States to implement SAMHSA's Strategic Prevention Framework in order to:

- Prevent the onset and reduce the progression of substance abuse, including childhood and underage drinking,
- Reduce substance abuse-related problems in communities, and
- Build prevention capacity and infrastructure at the State and community levels.

The Strategic Prevention Framework is built on a community-based risk and protective factors approach to prevention and a series of guiding principles that can be operationalized at the Federal, State and community levels. Although the direct recipients of SPF SIG funds will be the States, SAMHSA envisions the SPF SIGs being implemented through partnerships between the States and communities. The SPF SIG grantees may retain 15 percent of the total grant award to provide leadership and coordination of the SPF project in the State, hire SPF SIG project staff, and implement the following State-level activities:

- Conduct a statewide needs assessment.
 - Establish and maintain a State Epidemiological Workgroup
- Note:** SAMHSA expects that an average of \$200,000 per year will be needed to support the needs assessment and State Epidemiological Workgroup activities.

- Develop a statewide Strategic Plan
- Conduct on-going monitoring and oversight of the SPF SIG project
- Conduct a State-level evaluation of the SPF SIG project
- Provide training and technical assistance to support the SPF SIG project

States must allocate a minimum of 85 percent of the total grant award to community-level organizations, or through sub State mechanisms to community-level organizations.

DATES: Applications are due on July 2, 2004.

FOR FURTHER INFORMATION CONTACT: For questions on program issues, contact: Mike Lowther, SAMHSA/CSAP, 5600 Fishers Lane, Rockwall II, Suite 930, Rockville, MD 20857, Phone: (301) 443-0369, E-Mail: mlowther@samhsa.gov, or Dave Robbins, SAMHSA/CSAP, 5600 Fishers Lane, Rockwall II, Suite 930, Rockville, MD 20857, Phone: (301) 443-0369, E-Mail: [drobbins@samhsa.gov](mailto:d Robbins@samhsa.gov).

For questions on grants management issues, contact: Edna Frazier, Division of Grants Management, Substance Abuse and Mental Health Services Administration/OPS, 5600 Fishers Lane, Rockwall II, Suite 630, Rockville, MD 20857, Phone: (301) 443-443-6816, E-mail: efrazier@samhsa.gov.

SUPPLEMENTARY INFORMATION: Catalogue of Federal Domestic Assistance (CFDA) No.: 93.243.

KEY DATES

Application deadline	Application deadline: July 2, 2004
Intergovernmental Review (E.O. 12372)	Letters from State Single Point of Contact (SPOC) are due no later than 60 days after application deadline.

Table of Contents

- I. Funding Opportunity Description
 - 1. Introduction
 - 2. Expectations
- II. Award Information
 - 1. Award Amount
 - 2. Funding Mechanism
- III. Eligibility Information
 - 1. Eligible Applicants
 - 2. Cost Sharing
 - 3. Other
- IV. Application and Submission Information
 - 1. Address to Request Application Package
 - 2. Content and Form of Application Submission
 - 3. Submission Dates and Times

- 4. Intergovernmental Review (E.O. 12372) Requirements
- 5. Funding Restrictions/Limitations
- 6. Other Submission Requirements
- V. Application Review Information
 - 1. Evaluation Criteria
 - 2. Review and Selection Process
- VI. Award Administration Information
 - 1. Award Notices
 - 2. Administrative and National Policy Requirements
 - 3. Reporting Requirements
- VII. Agency Contacts
- Appendix A: Checklist for Formatting Requirements and Screenout Criteria for SAMHSA Grant Applications

- Appendix B: Glossary
- Appendix C: National Registry of Effective Prevention Programs
- Appendix D: Performance Measures for the SPF SIG Program

I. Funding Opportunity Description

1. Introduction

As authorized under Section 516 of the Public Health Service Act, the Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Substance Abuse Prevention (CSAP) announces the availability of